OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell

Regular Trading of OABI Stock to Commence November 2, 2022

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced its Chief Executive Officer Matt Foehr will ring the opening bell of the Nasdaq Stock Market in a ceremony today at 9:30 a.m. Eastern time. He will be joined by members of OmniAb’s leadership team and Board of Directors to celebrate its listing on the exchange, where regular trading will begin under the ticker OABI on November 2, 2022.

“We are honored to be ringing the Nasdaq opening bell to celebrate OmniAb becoming an independent publicly-traded company, after the completion of the spin-off from Ligand Pharmaceuticals,” stated Mr. Foehr. “We are excited for the future and to build shareholder value as our partners leverage our technology to access the most diverse antibody repertoires and cutting-edge screening technologies to discover next-generation therapeutics. I want to thank our employees, directors, partners and shareholders for supporting our mission to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies.”

The market opening ceremony will be livestreamed and can be viewed here.

About OmniAb^®

OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

OmniAb Inc.
investors@OmniAb.com
Twitter @OmniAbTech
(510) 250-7801

LHA Investor Relations
Yvonne Briggs
ybriggs@lhai.com
(310) 691-7100